Cargando…
Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer
Great advances in cancer treatment have been undertaken in the last years as a consequence of the development of new antitumoral drugs able to target cancer cells with decreasing side effects and a better understanding of the behavior of neoplastic cells during invasion and metastasis. Specifically,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569977/ https://www.ncbi.nlm.nih.gov/pubmed/36232652 http://dx.doi.org/10.3390/ijms231911352 |
_version_ | 1784809991799046144 |
---|---|
author | De Lama-Odría, María del Carmen del Valle, Luis J. Puiggalí, Jordi |
author_facet | De Lama-Odría, María del Carmen del Valle, Luis J. Puiggalí, Jordi |
author_sort | De Lama-Odría, María del Carmen |
collection | PubMed |
description | Great advances in cancer treatment have been undertaken in the last years as a consequence of the development of new antitumoral drugs able to target cancer cells with decreasing side effects and a better understanding of the behavior of neoplastic cells during invasion and metastasis. Specifically, drug delivery systems (DDS) based on the use of hydroxyapatite nanoparticles (HAp NPs) are gaining attention and merit a comprehensive review focused on their potential applications. These are derived from the intrinsic properties of HAp (e.g., biocompatibility and biodegradability), together with the easy functionalization and easy control of porosity, crystallinity and morphology of HAp NPs. The capacity to tailor the properties of DLS based on HAp NPs has well-recognized advantages for the control of both drug loading and release. Furthermore, the functionalization of NPs allows a targeted uptake in tumoral cells while their rapid elimination by the reticuloendothelial system (RES) can be avoided. Advances in HAp NPs involve not only their use as drug nanocarriers but also their employment as nanosystems for magnetic hyperthermia therapy, gene delivery systems, adjuvants for cancer immunotherapy and nanoparticles for cell imaging. |
format | Online Article Text |
id | pubmed-9569977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95699772022-10-17 Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer De Lama-Odría, María del Carmen del Valle, Luis J. Puiggalí, Jordi Int J Mol Sci Review Great advances in cancer treatment have been undertaken in the last years as a consequence of the development of new antitumoral drugs able to target cancer cells with decreasing side effects and a better understanding of the behavior of neoplastic cells during invasion and metastasis. Specifically, drug delivery systems (DDS) based on the use of hydroxyapatite nanoparticles (HAp NPs) are gaining attention and merit a comprehensive review focused on their potential applications. These are derived from the intrinsic properties of HAp (e.g., biocompatibility and biodegradability), together with the easy functionalization and easy control of porosity, crystallinity and morphology of HAp NPs. The capacity to tailor the properties of DLS based on HAp NPs has well-recognized advantages for the control of both drug loading and release. Furthermore, the functionalization of NPs allows a targeted uptake in tumoral cells while their rapid elimination by the reticuloendothelial system (RES) can be avoided. Advances in HAp NPs involve not only their use as drug nanocarriers but also their employment as nanosystems for magnetic hyperthermia therapy, gene delivery systems, adjuvants for cancer immunotherapy and nanoparticles for cell imaging. MDPI 2022-09-26 /pmc/articles/PMC9569977/ /pubmed/36232652 http://dx.doi.org/10.3390/ijms231911352 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review De Lama-Odría, María del Carmen del Valle, Luis J. Puiggalí, Jordi Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer |
title | Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer |
title_full | Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer |
title_fullStr | Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer |
title_full_unstemmed | Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer |
title_short | Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer |
title_sort | hydroxyapatite biobased materials for treatment and diagnosis of cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569977/ https://www.ncbi.nlm.nih.gov/pubmed/36232652 http://dx.doi.org/10.3390/ijms231911352 |
work_keys_str_mv | AT delamaodriamariadelcarmen hydroxyapatitebiobasedmaterialsfortreatmentanddiagnosisofcancer AT delvalleluisj hydroxyapatitebiobasedmaterialsfortreatmentanddiagnosisofcancer AT puiggalijordi hydroxyapatitebiobasedmaterialsfortreatmentanddiagnosisofcancer |